EA202092369A1 - Конъюгаты фосфолипид-флаваглин и способы их применения для целенаправленной терапии рака - Google Patents

Конъюгаты фосфолипид-флаваглин и способы их применения для целенаправленной терапии рака

Info

Publication number
EA202092369A1
EA202092369A1 EA202092369A EA202092369A EA202092369A1 EA 202092369 A1 EA202092369 A1 EA 202092369A1 EA 202092369 A EA202092369 A EA 202092369A EA 202092369 A EA202092369 A EA 202092369A EA 202092369 A1 EA202092369 A1 EA 202092369A1
Authority
EA
Eurasian Patent Office
Prior art keywords
flavaglin
phospholipid
methods
conjugates
application
Prior art date
Application number
EA202092369A
Other languages
English (en)
Inventor
Джеррод Лонгкор
Original Assignee
Селлектар Байосайенсиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Селлектар Байосайенсиз, Инк. filed Critical Селлектар Байосайенсиз, Инк.
Publication of EA202092369A1 publication Critical patent/EA202092369A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F19/00—Metal compounds according to more than one of main groups C07F1/00 - C07F17/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/022—Boron compounds without C-boron linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Изобретение относится к молекулам фосфолипидного эфира (PLE). Также представлены конъюгаты фосфолипид-флаваглин. Конъюгат фосфолипид-флаваглин может включать в себя PLE, конъюгированный с флаваглином через линкер. Дополнительно раскрываются способы лечения рака у субъекта и способы нацеливания лекарственного средства на опухолевую или раковую клетку у субъекта.
EA202092369A 2018-04-10 2019-04-10 Конъюгаты фосфолипид-флаваглин и способы их применения для целенаправленной терапии рака EA202092369A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862655659P 2018-04-10 2018-04-10
PCT/US2019/026853 WO2019200017A1 (en) 2018-04-10 2019-04-10 Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy

Publications (1)

Publication Number Publication Date
EA202092369A1 true EA202092369A1 (ru) 2021-01-26

Family

ID=68164618

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092369A EA202092369A1 (ru) 2018-04-10 2019-04-10 Конъюгаты фосфолипид-флаваглин и способы их применения для целенаправленной терапии рака

Country Status (14)

Country Link
US (1) US20210163513A1 (ru)
EP (1) EP3773544A4 (ru)
JP (1) JP7402172B2 (ru)
KR (1) KR20200140835A (ru)
CN (1) CN112272556B (ru)
AU (2) AU2019251483B2 (ru)
BR (1) BR112020020759A2 (ru)
CA (1) CA3095515A1 (ru)
EA (1) EA202092369A1 (ru)
IL (2) IL277875A (ru)
MA (1) MA52247A (ru)
MX (1) MX2020010741A (ru)
SG (1) SG11202009549YA (ru)
WO (1) WO2019200017A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107708702A (zh) 2014-11-17 2018-02-16 塞勒克塔生物科学有限公司 磷脂醚类似物作为靶向癌症的药物载体
US20230066517A1 (en) * 2019-09-12 2023-03-02 Cellectar Biosciences, Inc. Phospholipid Ether Conjugates as Cancer-Targeting Drug Vehicles

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4132344A1 (de) * 1991-09-27 1993-04-01 Max Planck Gesellschaft Verfahren zur herstellung eines arzneimittels zur oralen oder topischen verabreichung bei der behandlung von leishmaniasis
DE4408011C1 (de) * 1994-03-10 1995-11-02 Max Delbrueck Centrum Pharmazeutisches Mittel zur Tumortherapie
WO2008150439A1 (en) 2007-06-01 2008-12-11 Cellectar, Inc. Compositions of phospholipid ether boronic acids and esters and methods for their synthesis and use
CN103944903B (zh) 2014-04-23 2017-02-15 福建联迪商用设备有限公司 一种多方授权的apk签名方法及系统
CN107708702A (zh) * 2014-11-17 2018-02-16 塞勒克塔生物科学有限公司 磷脂醚类似物作为靶向癌症的药物载体
EP3464280B1 (en) * 2016-06-06 2021-10-06 F. Hoffmann-La Roche AG Silvestrol antibody-drug conjugates and methods of use
KR20190037226A (ko) * 2016-06-14 2019-04-05 셀렉타 바이오사이언시스, 인코퍼레이티드 순환 종양 세포의 식별 및 단리를 위한 인지질 에테르 유사체

Also Published As

Publication number Publication date
CN112272556B (zh) 2023-12-19
JP2021521169A (ja) 2021-08-26
US20210163513A1 (en) 2021-06-03
BR112020020759A2 (pt) 2021-01-19
AU2019251483B2 (en) 2021-08-05
EP3773544A1 (en) 2021-02-17
CN112272556A (zh) 2021-01-26
WO2019200017A1 (en) 2019-10-17
IL277875A (en) 2020-11-30
AU2019251483A1 (en) 2020-10-15
MX2020010741A (es) 2020-11-09
MA52247A (fr) 2021-02-17
JP7402172B2 (ja) 2023-12-20
CA3095515A1 (en) 2019-10-17
SG11202009549YA (en) 2020-10-29
AU2021261949A1 (en) 2021-12-02
IL304245A (en) 2023-09-01
KR20200140835A (ko) 2020-12-16
EP3773544A4 (en) 2022-04-13

Similar Documents

Publication Publication Date Title
CY1122855T1 (el) Θεραπευτικα συστατικα δεσμευσης κυτταρικης επιφανειας με αματοξινη για τη θεραπεια ογκου
MX2023001685A (es) Anticuerpo anti-cdh6 y conjugado farmaco-anticuerpo anti-cdh6.
NZ741261A (en) Pyrrolobenzodiazepine antibody drug conjugates and methods of use
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
EA201790404A1 (ru) Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака
MX2019010804A (es) Compuestos de benzazepina, conjugados y usos de los mismos.
EA201992081A1 (ru) Конъюгирование цитотоксических лекарственных средств посредством бис-связывания
CY1123983T1 (el) Ειδικα σε axl συζευγματα αντισωματος-φαρμακου για τη θεραπεια καρκινου
NZ739780A (en) Compositions, combinations and related methods for photoimmunotherapy
SG11201807936VA (en) Cell injury inducing therapeutic drug for use in cancer therapy
EA201590622A1 (ru) Конъюгаты для доставки лекарственного средства, содержащие не встречающиеся в природе аминокислоты, и способы применения
MX2015011583A (es) Derivados de amatoxina.
PH12016500246A1 (en) 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
MX2020012997A (es) Conjugados de anticuerpo modulador de empalme-farmaco y metodos de uso.
BR112012026213A2 (pt) pirrolobenzodiazepinas e conjugados das mesmas
EA201700181A1 (ru) Композиции аденозиндеаминазы-2 (ада-2), их варианты и способы использования
MX2019001302A (es) Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
CY1112278T1 (el) Κυτταροτοξικοι παραγοντες που περιεχουν νεα παραγωγα τομαυμυciν και η θεραπευτικη χρηση τους
UA110370C2 (en) Conjugates of amatoxin with improved linkages
UA111341C2 (uk) Аматоксиновий кон'югат з покращеними лінкерами
EA201490974A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С ДЕЛЕЦИОННЫМ МУТАНТОМ vIII ЭПИДЕРМАЛЬНОГО ФАКТОРА РОСТА
MX2016007578A (es) Compuestos de conjugado anticuerpo-farmaco dimerico de 1-(clorometil)-2,3-dihidro-1h-benzo [e] indol, y metodos de uso y tratamiento.
MX2023002599A (es) Conjugados de compuestos de tubulisina cuaternizada.
MX2021015533A (es) Anticuerpos anti-mesotelina e inmunoconjugados de los mismos.
MY196747A (en) Cell injury inducing therapeutic drug for use in cancer therapy